Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more
Preface Preface Author Cloud Assistant Antibody-drug conjugates (ADCs) are a class of emerging drugs that combine the advantages of both antibodies and small molecule toxins. Compared to traditional cytotoxic drugs, ADCs have the advantages of strong targeting and fewer side effects, making them promising in the field of tumor therapy. To date, 11 ADC drugs … Read more
Introduction Antibody-drug conjugates (ADCs) typically consist of: highly specific and high-affinity antibodies, stable linkers, and potent small-molecule cytotoxic drugs1. The key to the development of ADCs lies in the selection of targets, antibodies, cytotoxic payloads, linkers, and the conjugation method. Among these, the conjugation method of ADCs directly determines the drug-to-antibody ratio (DAR), the distribution … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxicity and side effects of traditional small molecule drugs while improving overall therapeutic efficiency. Currently, there are 13 … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxic side effects of traditional small molecule drugs and enhancing overall therapeutic efficiency. Currently, there are 13 ADC … Read more
Author | Little Fish Periodically, major pharmaceutical media and authoritative journals summarize the development of ADCs. Recently, a review on ADCs published by the internationally renowned journal ACS caught our attention. As a member of CAS (American Chemical Society), Janet M. Sasso’s team innovatively used patents and articles related to ADCs within CAS as data … Read more
Representative ADC Technology Platforms As a combination drug, any component of an ADC can be replaced or modified.Therefore, the ADC combination technology platform has significant extensibility, allowing for the iterative combination of a rich variety of products.The development history of internationally leading ADC companies is rooted in having a competitive platform.Table 1 lists several representative … Read more
Known as magic bullets, ADCs have been highly praised in recent years. The design concept of these drugs is clear: to utilize the high specificity of antigen-antibody binding to selectively deliver toxins to antigen-positive cells, thereby selectively killing target cells and reducing damage to normal cells. However, like other drugs, the actual performance of ADCs … Read more
Introduction Antibody-Drug Conjugates (ADCs) are targeted therapies that consist of antibodies, linkers, and cytotoxic drugs, using monoclonal antibodies as carriers to efficiently deliver cytotoxic drugs to target tumor cells in a targeted manner, combining the powerful killing effect of traditional chemotherapy with the tumor-targeting capability of antibody drugs. An ideal ADC maintains stability in the … Read more
Source: Xiaoyao Shuo Yao Introduction Antibody-drug conjugates (ADC) are a powerful cancer treatment method that combines monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs linked by a linker. ADCs utilize the specificity of antibodies for their target antigens, combined with the potency of cytotoxic drugs, to selectively kill tumor cells expressing the target … Read more